Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | TDP2 | O95551 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | CCR4 | P51679 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31320140 | 1.00 | RAB9A (0.63) | RAB9AALDH1A1NPC1LMNAKMT2A | |
| SCHEMBL29992512 | 0.79 | MAOA (0.55) | RAB9AALDH1A1NPC1KMT2AMAOA | |
| SCHEMBL19385517 | 0.78 | MAPT (1.00) | RAB9AALDH1A1NPC1LMNAKMT2A | |
| SCHEMBL28600044 | 0.74 | MAPT (0.75) | RAB9AALDH1A1NPC1LMNAKMT2A | |
| SCHEMBL28595390 | 0.74 | MAPT (0.75) | RAB9AALDH1A1NPC1LMNAKMT2A | |
| SCHEMBL28600039 | 0.73 | MAPT (0.74) | RAB9AALDH1A1NPC1LMNAKMT2A | |
| SCHEMBL22013244 | 0.72 | ALDH1A1 (0.71) | RAB9AALDH1A1NPC1LMNAKMT2A | |
| SCHEMBL13841371 | 0.72 | NPC1 (0.57) | ALDH1A1NPC1KMT2AMAOACCR4 | |
| SCHEMBL21964225 | 0.71 | MAPT (0.70) | RAB9AALDH1A1NPC1LMNAKMT2A | |
| SCHEMBL31320231 | 0.71 | ALDH1A1 (0.70) | RAB9AALDH1A1NPC1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213978-B2 | Madrasin-derivative compounds, composition and uses thereof for treating cancer | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-02-04 | — | — | US | claimed |
| EP-3880205-B1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | ROUSSY INST GUSTAVE (FR) | 2023-08-30 | — | — | EP | claimed |
| US-20220047597-A1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | INSTITUT GUSTAVE ROUSSY (FR) | 2022-02-17 | — | — | US | claimed |
| EP-3880205-A1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | Institut Gustave-Roussy (FR) | 2021-09-22 | — | — | EP | claimed |
| CN-113226323-A | Madricin derivative compounds, compositions and uses thereof for treating cancer | 法国古士塔柏罗斯学院 | 2021-08-06 | — | — | CN | claimed |
| WO-2020099650-A1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | INSTITUT GUSTAVE ROUSSY (FR) | 2020-05-22 | — | — | WO | claimed |
| US-12213978-B2 | Madrasin-derivative compounds, composition and uses thereof for treating cancer | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-02-04 | — | — | US | disclosed |
| EP-3880205-B1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | ROUSSY INST GUSTAVE (FR) | 2023-08-30 | — | — | EP | disclosed |
| EP-3880205-B1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | ROUSSY INST GUSTAVE (FR) | 2023-08-30 | — | — | EP | disclosed |
| US-20220047597-A1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | INSTITUT GUSTAVE ROUSSY (FR) | 2022-02-17 | — | — | US | disclosed |
| WO-2020099650-A1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | INSTITUT GUSTAVE ROUSSY (FR) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047597-A1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | PTPRS, PTMS, PTPRC | RAB9A 1993/4885ALDH1A1 1922/4885NPC1 1449/4885 |
| US-12213978-B2 | Madrasin-derivative compounds, composition and uses thereof for treating cancer | PTPRS, PTMS, PTPRC | RAB9A 1993/4885ALDH1A1 1922/4885NPC1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.